Myconail (Ciclopirox)

Ciclopirox, the active ingredient in Myconail, is an antifungal presented as a topical formulation for topical use. It treats fungal skin infections such as tinea corporis, tinea pedis, tinea cruris, cutaneous candidiasis, and onychomycosis in adults and children and is marketed across European Union member states with a focus on dermatological care.

GNH USA supplies Myconail as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Myconail (ciclopirox) is used to treat fungal skin conditions by inhibiting fungal growth.

Dermatophytosis (tinea corporis, pedis, cruris): clears infection and relieves itching, scaling and redness. Candidiasis of the skin: reduces yeast proliferation and promotes resolution of erythematous lesions. Onychomycosis: facilitates clearance of nail fungus and improves nail appearance.

Topical ciclopirox may cause local skin reactions, ranging from mild irritation to rare severe hypersensitivity.

Common Side Effects: - Itching or pruritus at the application site - Burning sensation - Redness or erythema - Dryness or flaking of skin - Mild irritation or stinging - Scaling or peeling

Serious or Rare Side Effects: - Severe allergic reaction (angioedema, anaphylaxis) - Contact dermatitis with blistering - Bullous skin eruptions - Stevens‑Johnson syndrome - Toxic epidermal necrolysis - Pronounced photosensitivity

When using Myconail, consider the following precautions to ensure safe and effective treatment.

Apply to intact skin only: avoid broken or inflamed areas. Avoid ocular contact: keep product away from eyes. Do not use on mucous membranes: refrain from applying to mouth or genital mucosa. Discontinue if severe irritation occurs: seek medical advice. Use only as directed by healthcare professional: follow prescribed regimen. Store at room temperature: keep in original container, protect from moisture and light.

Ciclopirox topical has limited systemic interactions, but certain co‑administered agents may affect tolerability or efficacy.

Major Interactions (Avoid): - Other topical antifungal agents (e.g., azole creams): may increase risk of skin irritation. - Topical corticosteroids applied simultaneously: can mask infection signs and reduce antifungal effectiveness.

Moderate Interactions (Monitor Closely): - Systemic antifungal therapy (e.g., oral itraconazole): monitor for overlapping toxicity. - Skin care products containing alcohol or harsh surfactants: may enhance local irritation. - Phototoxic agents (e.g., psoralen): increase risk of photosensitivity when combined with ciclopirox.